Sutro Biopharma Inc (STRO)
4.15
-0.20
(-4.60%)
USD |
NASDAQ |
May 10, 16:00
4.14
-0.01
(-0.24%)
After-Hours: 20:00
Sutro Biopharma Revenue (Quarterly): 113.72M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 113.72M |
September 30, 2023 | 16.92M |
June 30, 2023 | 10.41M |
March 31, 2023 | 12.67M |
December 31, 2022 | 8.632M |
September 30, 2022 | 25.15M |
June 30, 2022 | 28.10M |
March 31, 2022 | 5.897M |
December 31, 2021 | 10.65M |
September 30, 2021 | 8.517M |
June 30, 2021 | 28.05M |
March 31, 2021 | 14.66M |
December 31, 2020 | 8.278M |
Date | Value |
---|---|
September 30, 2020 | 17.82M |
June 30, 2020 | 9.469M |
March 31, 2020 | 7.152M |
December 31, 2019 | 11.30M |
September 30, 2019 | 12.28M |
June 30, 2019 | 10.52M |
March 31, 2019 | 8.629M |
December 31, 2018 | 19.09M |
September 30, 2018 | 7.836M |
June 30, 2018 | 5.704M |
March 31, 2018 | 5.793M |
December 31, 2017 | 4.04M |
September 30, 2017 | 17.50M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
5.897M
Minimum
Mar 2022
113.72M
Maximum
Dec 2023
18.96M
Average
11.30M
Median
Dec 2019
Revenue (Quarterly) Benchmarks
AnaptysBio Inc | 9.005M |
ABVC BioPharma Inc | 0.0022M |
Reviva Pharmaceuticals Holdings Inc | -- |
Flora Growth Corp | 17.98M |
Journey Medical Corp | 15.26M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 31.06M |
Total Expenses (Quarterly) | 70.57M |
EPS Diluted (Quarterly) | 0.52 |
Enterprise Value | -52.34M |
Profit Margin (Quarterly) | 27.32% |
Earnings Yield | -42.89% |
Normalized Earnings Yield | -46.22 |